Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 11/20 | 0.44 |
| ▸ | CA1 | P00915 | 11/20 | 0.44 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CHUK | O15111 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 3/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995679 | 0.85 | CA2 (0.39) | CA2ENPP3CA9CA1CA12 | |
| SCHEMBL1474323 | 0.78 | CA2 (0.62) | CA2CA9CA1CA12CA4 | |
| SCHEMBL14995676 | 0.77 | CA2 (0.51) | CA2ENPP3CA9CA1CA12 | |
| SCHEMBL5117367 | 0.73 | CA2 (0.40) | CA2ENPP3CA9CA1CA12 | |
| SCHEMBL1476189 | 0.71 | JAK3 (0.57) | CA2 | |
| SCHEMBL1474777 | 0.71 | AURKA (0.56) | CA2 | |
| SCHEMBL1474284 | 0.69 | AURKA (0.61) | CA2 | |
| SCHEMBL15651718 | 0.68 | CA1 (0.61) | CA2CA9CA1CA12CA4 | |
| SCHEMBL4970405 | 0.67 | CA2 (0.59) | CA2 | |
| Ammonia Solution, Strong SCHEMBL1890157 | 0.66 | CDK2 (0.42) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815848-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CA2 4491/4885ENPP3 1382/4885CA9 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.